NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS).
Dear Shareholders,
In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis' headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. without the physical presence of the shareholders.
The Vote
Under these conditions, shareholders are invited to vote remotely, prior to the General Meeting, by giving a proxy to the Chairman or by returning the voting form.
Exceptionally, we invite not to give a proxy to a third party to represent you at the meeting insofar as the meeting will be held without the physical presence of the shareholders and therefore of any third party proxies, and to give preference to voting by mail or to give a proxy to the Chairman.
In view of the uncertainty surrounding postal deadlines in the current circumstances, shareholders are advised to make use, when possible, of electronic means of communications in their dealings and communications relating to this general meeting.
Requests for the voting form must reach Société Générale via the shareholder's financial intermediary at one of the addresses indicated above, at least six days before the date of the meeting, i.e. no later than June 23, 2020.
Only duly completed voting forms that are received at Société Générale at one the addresses indicated above at least three days before the scheduled date of the meeting, i.e. no later than June 26, 2020, and accompanied by the certificate of participation issued by an authorised intermediary for bearer shares, will be taken into account.
Requests to add draft resolutions or items to the agenda
The draft resolutions submitted by the shareholders and the list of items added to the agenda at their request will be posted on the Company's website www.cellectis.com as soon as the aforementioned conditions are fulfilled.
Questions in writing
Any shareholder may also formulate written questions. These questions should be addressed:
- To the head office at 8, rue de la Croix Jarry - 75013 Paris, France by registered letter with acknowledgement of receipt, addressed to the Chairman of the Board of Directors, or
- to the following email address [email protected];
four business days at the latest before the General Meeting, i.e. no later than June 23, 2020, accompanied by a certificate of registration either in the registered securities accounts or in the bearer securities accounts kept by the authorised intermediary.
Answers will be posted on the Company's website www.cellectis.com.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).
TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [email protected]
PDF available: http://ml.globenewswire.com/Resource/Download/f1f3db6d-2218-40f4-90f1-b28e714c39e0
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
